AAAAAA
Results: 1-25/28
Authors:
Hilleman, DE
Citation: De. Hilleman, Pharmacoeconomics of combination antihypertensive therapy, BL PRESS M, 6, 2001, pp. S31-S36
Authors:
Friedman, M
Hilleman, DE
Citation: M. Friedman et De. Hilleman, Economic burden of chronic obstructive pulmonary disease - Impact of new treatment options, PHARMACOECO, 19(3), 2001, pp. 245-254
Authors:
Spinler, SA
Hilleman, DE
Cheng, JWM
Howard, PA
Mauro, VF
Lopez, LM
Munger, MA
Gardner, SF
Nappi, JM
Citation: Sa. Spinler et al., New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines, ANN PHARMAC, 35(5), 2001, pp. 589-617
Authors:
Hilleman, DE
Reyes, AP
Wurdeman, RL
Faulkner, M
Citation: De. Hilleman et al., Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension, J HUM HYPER, 15(8), 2001, pp. 559-565
Authors:
Faulkner, MA
Hilleman, DE
Destache, CJ
Mooss, AN
Citation: Ma. Faulkner et al., Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome, PHARMACOTHE, 21(9), 2001, pp. 1055-1060
Authors:
Lenz, TL
Wurdeman, RL
Hilleman, DE
Citation: Tl. Lenz et al., Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine, PHARMACOTHE, 21(8), 2001, pp. 898-903
Authors:
Hilleman, DE
Bauman, JL
Citation: De. Hilleman et Jl. Bauman, Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: An evidence-based review, PHARMACOTHE, 21(5), 2001, pp. 556-575
Authors:
Hilleman, DE
Wurdeman, RL
Lenz, TL
Citation: De. Hilleman et al., Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease, PHARMACOTHE, 21(4), 2001, pp. 410-415
Authors:
Hilleman, DE
Monaghan, MS
Ashby, CL
Mashni, JE
Woolley, K
Amato, CM
Citation: De. Hilleman et al., Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease, PHARMACOTHE, 21(11), 2001, pp. 1415-1421
Authors:
Nair, CK
Khan, IA
Esterbrooks, DJ
Ryschon, KL
Hilleman, DE
Citation: Ck. Nair et al., Diagnostic and prognostic value of holter-detected ST-segment deviation inunselected patients with chest pain referred for coronary angiography - A long-term follow-up analysis, CHEST, 120(3), 2001, pp. 834-839
Authors:
Hilleman, DE
Citation: De. Hilleman, New approaches to the management of AMI: Fibrinolysis plus GP IIb/IIIa receptor blockade, FORMULARY, 35(9), 2000, pp. 738
Authors:
Hilleman, DE
Citation: De. Hilleman, Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension, AM J HEAL S, 57(19), 2000, pp. S8-S11
Authors:
Lenz, TL
Hilleman, DE
Citation: Tl. Lenz et De. Hilleman, Aggrenox: A fixed-dose combination of aspirin and dipyridamole, ANN PHARMAC, 34(11), 2000, pp. 1283-1290
Authors:
Seyedroudbari, A
Kessler, ER
Mooss, AN
Wurdeman, RL
Bala, M
Hilleman, DE
Citation: A. Seyedroudbari et al., Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA, J THROMB TH, 9(3), 2000, pp. 303-308
Authors:
Lenz, TL
Hilleman, DE
Citation: Tl. Lenz et De. Hilleman, Dofetilide, a new class III antiarrhythmic agent, PHARMACOTHE, 20(7), 2000, pp. 776-786
Authors:
Skrabal, MZ
Stading, JA
Behmer-Miller, KA
Hilleman, DE
Citation: Mz. Skrabal et al., Advances in the treatment of congestive heart failure: New approaches for an old disease, PHARMACOTHE, 20(7), 2000, pp. 787-804
Authors:
Hilleman, DE
Heineman, SM
Foral, PA
Citation: De. Hilleman et al., Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study, PHARMACOTHE, 20(7), 2000, pp. 819-822
Authors:
Faulkner, MA
Wadibia, EC
Lucas, BD
Hilleman, DE
Citation: Ma. Faulkner et al., Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: A randomized, controlled trial, PHARMACOTHE, 20(4), 2000, pp. 410-416
Authors:
Lenz, TL
Hilleman, DE
Citation: Tl. Lenz et De. Hilleman, Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter, DRUGS TODAY, 36(11), 2000, pp. 759-771
Authors:
Hilleman, DE
Dewan, N
Malesker, M
Friedman, M
Citation: De. Hilleman et al., Pharmacoeconomic evaluation of COPD, CHEST, 118(5), 2000, pp. 1278-1285
Authors:
Rovang, KS
Arouni, AJ
Mohiuddin, SM
Tejani, A
Hilleman, DE
Citation: Ks. Rovang et al., Effect of estrogen on exercise electrocardiograms in healthy postmenopausal women, AM J CARD, 86(4), 2000, pp. 477
Authors:
Mooss, AN
Wurdeman, RL
Mohiuddin, SM
Reyes, AP
Sugimoto, JT
Scott, W
Hilleman, DE
Seyedroudbari, A
Citation: An. Mooss et al., Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery, AM HEART J, 140(1), 2000, pp. 176
Authors:
Hilleman, DE
Ryschon, KL
Mohiuddin, SM
Wurdeman, RL
Citation: De. Hilleman et al., Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation, J HUM HYPER, 13(7), 1999, pp. 477-483
Authors:
Wurdeman, RL
Mooss, AN
Mohiuddin, SM
Lucas, BD
Ryschon, KL
Hilleman, DE
Citation: Rl. Wurdeman et al., Comparison of 24-hour ambulatory blood pressure data in hypertensive patients switched from nifedipine-GITS to nifedipine-CC, PHARMACOTHE, 19(1), 1999, pp. 94-100
Authors:
Hilleman, DE
Phillips, JO
Mohiuddin, SM
Ryschon, KL
Pedersen, CA
Citation: De. Hilleman et al., A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia, CLIN THER, 21(3), 1999, pp. 536-562